Bright Minds Biosciences (DRUG) KOL Event summary

Introduction and agenda

• Presentation and webcast focused on advancing therapies for Prader-Willi Syndrome (PWS), including updates on ongoing epilepsy studies and the Phase 2a NOVA study evaluating BMB-101.

• Agenda included scientific and clinical context, unmet needs in PWS, development strategy, clinical assessment tools, and a Q&A session.

KOL background and credentials

• Dr. Jennifer Miller: Pediatric Endocrinologist, University of Florida, follows over 500 PWS patients globally and has extensive clinical trial experience.

• Dr. Theresa Strong: Co-founder and Director of Research at the Foundation for Prader-Willi Research, directs its grant program, and is a parent of a PWS patient.

• Elizabeth Roof: Vanderbilt University, expert in PWS clinical research and outcome measure development, with nearly 30 years of experience and over 450 individuals evaluated.

Market insights and analysis

• PWS is a rare genetic disorder affecting about 10,000 in the U.S. and 400,000 globally, with a $4.6B U.S. market opportunity based on current pricing.

• PWS affects 1 in 15,000 live births and is characterized by hyperphagia and significant neurobehavioral challenges.

• Existing therapies inadequately address both hyperphagia and neuropsychiatric symptoms, leaving most symptoms unaddressed and highlighting a high unmet need.